$1.17
−0.36 (−23.53%)Oct 27, 2026, 1:51 PM ET
Market Closed
Video Interviews
View All Interviews →
Company Overview
Azitra, Inc. is a pre-clinical biopharmaceutical company focused on developing precise treatments for various dermatological conditions. They innovate by utilizing engineered proteins and live biotherapeutic products to address skin diseases. The company's pipeline features several key therapeutic candidates: ATR-12: A genetically modified strain of S. epidermidis intended to treat Netherton syndrome, a specific skin disorder. ATR-04: Another modified S. epidermidis strain, designed to alleviate the papulopustular rash commonly experienced by cancer patients undergoing epidermal growth factor receptor inhibitor therapy. ATR-01: An engineered recombinant human filaggrin protein developed for the treatment of ichthyosis vulgaris, another dermatological ailment. Founded in 2014, Azitra, Inc. operates from its headquarters in Branford, Connecticut.
Key Highlights
- Biotechnology · Healthcare
- Led by Francisco D. Salva
- 13 employees
- Based in Branford, CT
Analyst Coverage
View All Coverage →No analyst coverage available.
Economic Calendar
View more →- Oct 28
FOMC Meeting
2:00 PM ET
- Oct 28
FOMC Rate Decision
2:00 PM ET
- Oct 28
FOMC Press Conference
2:30 PM ET
- Oct 29
Initial Jobless Claims
8:30 AM ET
Crypto Prices
View more →
Bitcoin (BTC)
81,060 +1.64%
Stock Quote
View Full Quote →AMEX:AZTR
Azitra, Inc.
$1.17
−0.36 (−23.53%)- Day Range
- $1.16 – $1.24
- 52 Week Range
- 0.518-7.63
- Volume
- 7,062,057
- Avg. Volume
- 2,257,655
- Market Cap
- 6.8M
- Shares Outstanding
- —
Market data delayed by 15 minutes.
Company Facts
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Branford, CT, US
- Incorporated
- Jun 20, 2023
- Website
